Safety and Effectiveness of Venetoclax/Rituximab in Bcri-Naïve and Bcri-Exposed Patients with Relapsed/Refractory CLL Under Real-Life Conditions - Data from the Observational Verve Study

Davide Rossi,Holger Hebart,Christoph Losem,Thomas Wolff,Xenia Schmidt,Kirsten Famulla,Burkhard Schmidt,Thomas Noesslinger,Ingo Schwaner

Blood（2021）

引用 0|浏览16

暂无评分

摘要

Background

更多

查看译文

关键词

venetoclax/rituximab,relapsed/refractory cll,bcri-exposed,real-life

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要